ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 1, 2009, Pages

  Murray, David B ^a,b   McMillan, Ronald ^a   Brower, Gregory L ^a   Janicki, Joseph S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Endothelin 1; Mast cell; Matrix metalloproteinase; TBC 3214

Indexed keywords

COLLAGEN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; GELATINASE A; MATRIX METALLOPROTEINASE; TBC 3214; UNCLASSIFIED DRUG; CYTOKINE; ISOXAZOLE DERIVATIVE; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART VENTRICLE REMODELING; HEART VENTRICLE VOLUME; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; ANIMAL; BLOOD VOLUME; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE FUNCTION; IN VITRO STUDY; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; BLOOD VOLUME; BLOTTING, WESTERN; COLLAGEN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; ISOXAZOLES; MALE; MAST CELLS; MATRIX METALLOPROTEINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 67650035110     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00968.2008     Document Type: Article

References (55)

1. Abraham D, Ponticos M, Nagase H. Connective tissue remodeling: cross-talk between endothelins and matrix metalloproteinases. Curr Vasc Pharmacol 3: 369-379, 2005.
2. Aharinejad S, Krenn K, Paulus P, Schafer R, Zuckermann A, Grimm M, Abraham D. Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients. Am J Transplant 5: 2185-2192, 2005.
3. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 39: 679-684, 2002.
4. Attina T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91: 825-831, 2005.
5. Bagnato A, Spinella F, Rosano L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 12: 761-772, 2005.
6. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 231: 653-695, 2006.
7. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 283: H518-H525, 2002.
8. Brower GL, Henegar JR, Janicki JS. Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol Heart Circ Physiol 271: H2071-H2078, 1996.
9. Brower GL, Janicki JS. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail 11: 548-556, 2005.
10. Brower GL, Janicki JS. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 280: H674-H683, 2001.
11. Caulfield JB, Janicki JS. Structure and function of myocardial fibrillar collagen. Technol Health Care 5: 95-113, 1997.
12. Cernacek P, Stewart DJ, Monge JC, Rouleau JL. The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol 81: 598-606, 2003.
13. Chancey AL, Brower GL, Janicki JS. Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function. Am J Physiol Heart Circ Physiol 282: H2152-H2158, 2002.
14. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105: 1983-1988, 2002.
15. Coulombe M, Battistini B, Stankova J, Pouliot P, Bissonnette EY. Endothelins regulate mediator production of rat tissue-cultured mucosal mast cells. Up-regulation of Th1 and inhibition of Th2 cytokines. J Leukoc Biol 71: 829-836, 2002.
16. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, Dargie HJ, McMurray JJ, Morton JJ. Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. Cardiovasc Res 39: 563-570, 1998.
17. Deschamps AM, Zavadzkas J, Murphy RL, Koval CN, McLean JE, Jeffords L, Saunders S, Sheats N, Stroud RE, Spinale FG. Interruption of endothelin signaling modifies membrane type-1 matrix metalloproteinase activity during ischemia and reperfusion. Am J Physiol Heart Circ Physiol 294: H875-H883, 2008.
18. Ding YF, Brower GL, Zhong Q, Murray D, Holland M, Janicki JS, Zhong J. Defective intracellular Ca2+ homeostasis contributes to myocyte dysfunction during ventricular remodelling induced by chronic volume overload in rats. Clin Exp Pharmacol Physiol 35: 827-835, 2008.
19. Duchman SM, Thohan V, Kalra D, Torre-Amione G. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol 15: 136-140, 2000.
20. Duda M, Konior A, Klemenska E, Beresewicz A. Preconditioning protects endothelium by preventing ET-1-induced activation of NADPH oxidase and xanthine oxidase in post-ischemic heart. J Mol Cell Cardiol 57: 553-569, 2006.
21. Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, Leclerc S, Moreau A, Moldovan F. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond) 110: 645-654, 2006.
22. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, Entman ML. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 98: 699-710, 1998.
23. Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 43: 111-126, 2001.
24. Gilles S, Zahler S, Welsch U, Sommerhoff CP, Becker BF. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res 60: 608-616, 2003.
25. Golfman LS, Hata T, Beamish RE, Dhalla NS. Role of endothelin in heart function in health and disease. Can J Cardiol 9: 635-653, 1993.
26. Gunasinghe SK, Ikonomidis J, Spinale FG. Contributory role of matrix metalloproteinases in cardiovascular remodeling. Curr Drug Targets Cardiovasc Haematol Disord 1: 75-91, 2001.
27. Gupta SK, Saxena A, Singh U, Arya DS. Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. Mol Cell Biochem 275: 67-74, 2005.
28. Janicki JS, Brower GL, Gardner JD, Chancey AL, Stewart JA Jr. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9: 33-42, 2004.
29. Janicki JS, Brower GL, Gardner JD, Forman MF, Stewart JA Jr, Murray DB, Chancey AL. Cardiac mast cell regulation of matrix metalloproteinase- related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 69: 657-665, 2006.
30. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96: 1042-1052, 1995.
31. Luscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hurlimann D, Philipp S, Notter T, Noll G, Ruschitzka F. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106: 2666-2672, 2002.
32. Matsushima H, Yamada N, Matsue H, Shimada S. The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. Eur J Immunol 34: 1910-1919, 2004.
33. Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjea D, Clouthier DE, Yanagisawa MM, Tsai M, Galli SJ. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432: 512-516, 2004.
34. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 85: 1374-1379, 1992.
35. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 274: R577-R595, 1998.
36. Metsarinne KP, Vehmaan-Kreula P, Kovanen PT, Saijonmaa O, Baumann M, Wang Y, Nyman T, Fyhrquist FY, Eklund KK. Activated mast cells increase the level of endothelin-1 mRNA in cocultured endothelial cells and degrade the secreted Peptide. Arterioscler Thromb Vasc Biol 22: 268-273, 2002.
37. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 110: 368-414, 2006.
38. Murray DB, Gardner JD, Brower GL, Janicki JS. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol 287: H2295-H2299, 2004.
39. Murray DB, Gardner JD, Brower GL, Janicki JS. Effects of nonselective endothelin receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats. Am J Physiol Heart Circ Physiol 294: H1251-H1257, 2008.
40. Murray DB, Gardner JD, Levick SP, Brower GL, Morgan LG, Janicki JS. Response of cardiac mast cells to atrial natriuretic peptide. Am J Physiol Heart Circ Physiol 293: H1216-H1222, 2007.
41. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89: 1573-1579, 1994.
42. Ozdemir R, Parlakpinar H, Polat A, Colak C, Ermis N, Acet A. Selective endothelin a (ET(A)) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 219: 142-149, 2006.
43. Perreault T, Berkenbosch JW, Barrington KJ, Decker ER, Wu C, Brock TA, Baribeau J. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res 50: 374-383, 2001.
44. Podesser BK, Siwik DA, Eberli FR, Sam F, Ngoy S, Lambert J, Ngo K, Apstein CS, Colucci WS. ETA-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol 280: H984-H991, 2001.
45. Reil JC, Gilles S, Zahler S, Brandl A, Drexler H, Hultner L, Matrisian LM, Welsch U, Becker BF. Insights from knock-out models concerning postischemic release of TNFalpha from isolated mouse hearts. J Mol Cell Cardiol 42: 133-141, 2007.
46. Rosano L, Di C, V, Spinella F, Nicotra MR, Natali PG, Bagnato A. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 6: 2003-2011, 2007.
47. Roy-Beaudry M, Martel-Pelletier J, Pelletier JP, M'Barek KN, Christgau S, Shipkolye F, Moldovan F. Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloprotease 1 and matrix metalloprotease 13 induction. Arthritis Rheum 48: 2855-2864, 2003.
48. Spieker LE, Luscher TF. Endothelin receptor antagonists in heart failure-a refutation of a bold conjecture? Eur J Heart Fail 5: 415-417, 2003.
49. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
50. Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail 8: S332-S338, 2002.
51. Suzuki Y, Yoshimaru T, Inoue T, Niide O, Ra C. Role of oxidants in mast cell activation. Chem Immunol Allergy 87: 32-42, 2005.
52. Wei CL, Valvano JW, Feldman MD, Nahrendorf M, Peshock R, Pearce JA. Volume catheter parallel conductance varies between endsystole and end-diastole. IEEE Trans Biomed Eng 54: 1480-1489, 2007.
53. Wolfreys K, Oliveira DB. Alterations in intracellular reactive oxygen species generation and redox potential modulate mast cell function. Eur J Immunol 27: 297-306, 1997.
54. Wu C, Chan MF, Stavros F, Raju B, Okun I, Mong S, Keller KM, Brock T, Kogan TP, Dixon RA. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40: 1690-1697, 1997.
55. Wu C, Decker ER, Blok N, Li J, Bourgoyne AR, Bui H, Keller KM, Knowles V, Li W, Stavros FD, Holland GW, Brock TA, Dixon RA. Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist. J Med Chem 44: 1211-1216, 2001.